PT - JOURNAL ARTICLE AU - Zachary Bloomgarden AU - Andrew Drexler TI - What role will ‘gliptins’ play in glycemic control? DP - 2008 Apr 01 TA - Cleveland Clinic Journal of Medicine PG - 305--310 VI - 75 IP - 4 4099 - http://www.ccjm.org/content/75/4/305.short 4100 - http://www.ccjm.org/content/75/4/305.full SO - Cleve Clin J Med2008 Apr 01; 75 AB - The gliptins, a new class of oral drugs for type 2 diabetes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levels of incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.